Inhibition of H3-Pser10 should therefore be viewed as a mechanism that both reduces the activation of NF-κB and its targeting to immediate-early inflammatory genes which are otherwise poorly controlled by corticosteroids alone patients with severe asthma. The gene discussed is NFKB1; the disease is asthma.